PT - JOURNAL ARTICLE AU - Daniel M. Weinberger AU - Ted Cohen AU - Forrest W. Crawford AU - Farzad Mostashari AU - Don Olson AU - Virginia E Pitzer AU - Nicholas G Reich AU - Marcus Russi AU - Lone Simonsen AU - Anne Watkins AU - Cecile Viboud TI - Estimating the early death toll of COVID-19 in the United States AID - 10.1101/2020.04.15.20066431 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.15.20066431 4099 - http://medrxiv.org/content/early/2020/04/18/2020.04.15.20066431.short 4100 - http://medrxiv.org/content/early/2020/04/18/2020.04.15.20066431.full AB - Background Efforts to track the severity and public health impact of the novel coronavirus, COVID-19, in the US have been hampered by testing issues, reporting lags, and inconsistency between states.Evaluating unexplained increases in deaths attributed to broad outcomes, such as pneumonia and influenza (P&I) or all causes, can provide a more complete and consistent picture of the burden caused by COVID-19.Methods We evaluated increases in the occurrence of deaths due to P&I above a seasonal baseline (adjusted for influenza activity) or due to any cause across the United States in February and March 2020. These estimates are compared with reported deaths due to COVID-19 and with testing data.Results There were notable increases in the rate of death due to P&I in February and March 2020. In a number of states, these deaths pre-dated increases in COVID-19 testing rates and were not counted in official records as related to COVID-19. There was substantial variability between states in the discrepancy between reported rates of death due to COVID-19 and the estimated burden of excess deaths due to P&I. The increase in all-cause deaths in New York and New Jersey is 1.5-3 times higher than the official tally of COVID-19 confirmed deaths or the estimated excess death due to P&I.Conclusions Excess P&I deaths provide a conservative estimate of COVID-19 burden and indicate that COVID-19-related deaths are missed in locations with inadequate testing or intense pandemic activity.Competing Interest StatementDMW has received consulting fees from Pfizer, Merck, GSK, and Affinivax for topics unrelated to this manuscript and is Principal Investigator on a research grant from Pfizer on an unrelated topic. VEP has received reimbursement from Merck and Pfizer for travel expenses to Scientific Input Engagements unrelated to the topic of this manuscript. All other authors report no relevant conflicts.Funding StatementDMW acknowledges support from grants R01AI123208 and R01AI137093 from the National Institute of Allergy and Infectious Diseases/National Institutes of Health. VEP acknowledges support from grants R01AI112970 and R01AI137093 from the National Institute of Allergy and Infectious Diseases/National Institutes of Health. NGR acknowledges support from grant R35GM119582 from the National Institute of General Medical Sciences/National Institutes of Health and 1U01IP001122 from the Centers for Disease Control and Prevention (CDC). TC acknowledges support from R01AI146555 from the National Institute of Allergy and Infectious Diseases/National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, New York City Department of Health and Mental Hygiene or CDC. LS acknowledges support from the Carlsberg Foundation grant # CF20-0046. FWC acknowledges support from NICHD grant 1DP2HD091799-01.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll analysis scripts and archives of the data are available from https://github.com/weinbergerlab/excess_pi_covid https://github.com/weinbergerlab/excess_pi_covid